📣 Save the Date!  |  ADDS Basel 2025  |  September 12, 2025 in Basel, Switzerland

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients

WARREN, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse® Phase 2b clinical trial (iNO-PF) for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) that supports actigraphy as a clinically meaningful endpoint will be the subject of a poster presentation at the 13th Annual Pulmonary Vascular Research Institute World Congress on Pulmonary Vascular Disease, which will take place January 31 through February 3, 2019, in Barcelona, Spain.

Read Full Article

Published date: January 28th, 2019
By: Bellerophon Therapeutics, Inc.

Back to Blog

Recent Articles

ActiGraph Partners with PDH to Advance DHTs in Clinical Research

PENSACOLA, FL, April 3, 2023–ActiGraph, a leading provider of wearable technology and scientific...

ActiGraph Establishes New Scientific Advisory Board of Clinical Research Experts

PENSACOLA, FL, June 2, 2022–ActiGraph, a leading provider of wearable technology-enabled...

VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials

Durham, NC – January 19, 2021–VeraSci, a global clinical research company offering eClinical...